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 Abstract 
Background: Marfan syndrome is an inherited condition, that affects many organ 
systems. The most obvious features are the skeletal abnormalities: tall stature, long 
limbs, arachnodactyly (spider hands). Ocular symptoms include severe myopia and 
lens luxation. The clinically most severe symptoms are cardiovascular: mitral valve 
insufficiency, aortic root enlargement and thoracic aortic aneurysms and dissections. 
Marfan syndrome is usually inherited in an autosomal dominant fashion, but in some 
families a recessive mode of inheritance has been described. Most cases are caused 
by mutations in the FBN1 gene. The phenotype is highly variable, also within 
families. The absence of the skeletal symptoms often leads to a failure to recognize 
the syndrome. The prevalence of Marfan syndrome is estimated to be 1 in 2500, in 
all populations, including Indonesia. There is some controversy in the literature 
regarding the involvement of transforming growth factor beat (TGFβ) in the etiology 
of Marfan syndrome, due to the fact that phosphorylation of the signal molecules 
smad2 and smad3 in some publications has been wrongly interpreted as exclusively 
caused by TGFβ, which is only one of the many ligands that can induce smad2/3 
phosphorylation.  
Clinical trials, testing the effect of losartan on aortic root dilatation and the growth 
of aneurysms, have shown conflicting results. In one study, the effect of losartan was 
only found in a subgroup of patients with a specific type of mutations, that lead to 
reduced amount of normal fibrillin 1 protein (haploinsufficiency). The distribution 
of this type of mutations in different population may explain the conflicting results 
of the trials. 
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INTRODUCTION 
 Marfan syndrome is named after the French 
pediatrician Antoine Bernard-Jean Marfan who 
described in 1896 a girl with arachnodactyly and long 
limbs1. The patient also had congenital contractures of 
the elbows and would not fulfill the current criteria for 
Marfan syndrome. She probably was suffering from a 
condition that we now call Contractural 
arachnodactyly, caused by mutations in the FBN2 
gene. 
 The clinical features of Marfan syndrome affect 
many systems of the body. The most obvious are the 
skeletal features, long limbs, tall stature, long thin 
fingers (arachnodactyly or spider fingers). The skeletal 
features can be scored objectively as: arm span more 
than 1.05 x body length; wrist sign (thumb and index 
finger can encircle the wrist of the other hand with at 
least one digit overlap) and thumb sign (when making 
a fist around the thumb, one digit of the thumb sticks 
out). The main neurological symptom is dural ectasias. 
The most severe symptoms are cardiovascular: mitral 
valve prolapse, aortic dilatation and thoracic aortic 
aneurysms and dissections, which may lead to sudden 
death2. However, I noticed in discussions with patients 
that they often consider the ocular symptoms, severe 
myopia and lens luxation, the worst for themselves, 
because the latter may lead to blindness.  
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 It is important to realize that the obvious skeletal 
features are not always present. Within families we 
often see carriers of the same pathogenic mutation, that 
have very different phenotypes3,4,5. This means that 
Marfan syndrome can be present without the typical 
“Marfan habitus”. The multitude of symptoms have led 
to defining clinical criteria for Marfan syndrome, 
named the Berlin nosology6, Ghent criteria7 and the 
revised Ghent nosology or criteria8, named after the 
symposia where the criteria were formulated and 
discussed. In the revised criteria, the major and minor 
criteria were replaced by a scoring system. Dural 
ectasias play a less important role in the criteria, 
because they are also very common in non-Marfan 
patients8,9. In Asian Marfan patients, the phenotype is 
different from patients with a European 
background10,11, so the criteria may have to be adapted 
for the Asian population. 
 One of the most important criteria for Marfan 
syndrome nowadays is the presence of a pathogenic 
mutation in the FBN1 gene. However, assessing the 
pathogenic effect of DNA variants is not a simple 
matter, as will be discussed below. Mutations in FBN1 
have also been demonstrated in patients that do not 
meet clinical criteria for Marfan syndrome12. The first 
mutation in FBN1 found in Marfan syndrome was 
published in 199113. There is still discussion on the 
subject of locus heterogeneity, but it is clear that the 
majority of Marfan syndrome patients have a 
pathogenic variant in the FBN1 gene14,15. In many 
countries, however, genetic testing is not readily 
available, so the use of the clinical criteria remains 
important in assessing Marfan syndrome and related 
phenotypes16,17. 
 In most cases, Marfan syndrome is inherited in an 
autosomal dominant fashion. However, autosomal 
recessive inheritance of mutations in FBN1 has also 
been demonstrated and should be taken into account in 
genetic counseling18,19.  
 
 
THE FBN1 GENE 
 The FBN1 gene is a very large gene, consisting of 
65 coding exons and one non-coding 5’exon, that cover 
237,482 nucleotides of genomic DNA and encode a 
messenger RNA of 8616 coding nucleotides, 395 
5’UTR and 2684 nucleotides 3’UTR. The FBN1 gene 
has a single large translated transcript 
(www.ensemble.org). We refer to transcript 
NM_000138.4 in this paper, when describing DNA 
variants on the cDNA.  
 
 
THE PROTEIN 
 The fibrillin 1 protein is a glycoprotein and is an 
important constituent of the elastic fibers in the large 
blood vessels (www.uniprot.org/uniprot/P35555). 
Fibrillin is important for tensile strength, whereas 
elastin is important for elasticity and extensibility. 
Consequently, the ratio of fibrillin and elastin has a 
large impact on the properties of the vessel wall. The 
cells that produce these structural proteins have no 
possible way of determining the amount of protein that 
has been produced, so the production of the proteins is 
not subject to any feedback regulation. Consequently, 
the gene dosage effect is very strong and null-alleles of 
the encoding genes have a strong effect on protein 
production and the ratio between elastin and fibrillin.  
 Apart from a function in structural properties of the 
vessel wall, fibrillin is also important as docking site 
for a number of inactive protein complexes, such as the 
latent TGF-β1, -2 and -320,21 and several matrix 
proteases, such as ADAMTS10 and ADAMTS1722. So 
fibrillin plays an important role in regulating the 
bioavailability of these growth factors and proteases. 
Other proteins that bind to fibrillin 1, such as the 
glycoproteins ADAMTSL2 and ADAMTSL4 
probably play a role in fibril formation22,23. 
 The fibrillin 1 protein has many repeated motifs 
(figure 1). The most common motifs are the epidermal 
growth factor-like domains (EGF-like domains). There 
are 47 EGF-like domains, 44 of these are calcium-
binding and 3 are non-calcium binding. Other repeated 
domains are the seven 8-cys domains (containing 8 
cysteine residues) and the two hybrid domains. Most of 
these domains function as docking sites for other 
proteins, as mentioned above. The loss function of 
these binding site probably leads to Mafan syndrome 
symptoms, but no clear genotype-phenotype 
correlations have been described, except for the 
domains involved in Weill-Marchesany syndrome or 
ectopia lentis22, 22. 
 
 
VARIANTS IN FBN1 AND THEIR 
INTERPRETATION 
 Since the publication of the first mutation in FBN1, 
pathogenic DNA variants have been found in all 65 
coding exons of this gene, which reflects the structural 
and docking functions of fibrillin 1, that can be 
disturbed by changes almost anywhere in the protein. 
This is also apparent from the extremely high level of 
evolutionary sequence conservation of fibrillin 1 
(Figure 2). In our diagnostic laboratory at Amsterdam 
University medical centers, 869 unique pathogenic 
DNA variants have been found in FBN1. Some 65% of 
Figure 1. Functional domains in fibrillin 1. cbEGF = calcium binding EGF-like domains. The signal peptide and 
propeptide are removed during transport and fibril formation. The domains are drawn to scale.  
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these mutations are missense mutations, that usually 
have a dominant effect, because the aberrant protein is 
incorporated in the extracellular matrix (ECM) and 
disturbs structure and function of the fibrils and 
interactions with other proteins. 
The international database lists 1847 unique variants in 
FBN1 (http://www.umd.be/FBN1/)24. Mutations in 
FBN1 range from single base substitutions to large 
genomic deletions or duplications25,26,27,28. Only 1.7% 
of the records in the database show large deletions or 
duplications (≥ 1 exon), whereas In our laboratory, 
12% of the pathogenic mutations are large deletions or 
duplications. This probably reflects the fact that our 
lab, as co-developers of the multiplex ligation 
dependent probe amplification (MLPA)30 technique 
that is used to detect this type of mutations, has tested 
all patients. Deletion of the entire gene is a recurrent 
and not a founder mutation, because deletions of 
different lengths, ranging from 1 Mb to 10 Mb, have 
been found in different families. Only the largest 
deletions were associated with additional features in 
the phenotype, such as mental retardation25,29. 
 The large number of missense mutations (65%) 
makes interpretation of variants difficult. In some cases 
the conclusions are not complicated. For example, in 
the EGF-like domains, the six cysteine residues play an 
important role in the formation of intramolecular three 
disulfide bridges, that determine the three-dimensional 
structure of these domains (figure 3). Therefore, the 
missense mutations involving loss or gain of a cysteine 
in these domains are considered to be pathogenic. The 
same can be said for the 8-cys and hybrid domains. 
Unfortunately, in the publication concerning the 
revised Ghent criteria (Dietz et al. 2010), the 
paragraphs about mutation interpretation contain 
several errors, which will lead to false assumptions 
about the pathogenic or benign effects of variants. For 
example, the consensus amino acid sequence  motif of 
the EGF domains is incorrectly represented as: 
((D/N)X(D/N)(E/Q)Xm(D/N)Xn(Y/F) with m and n 
representing variable numbers of residues; D aspartic 
acid, N asparagine, E glutamic acid, Q glutamine, Y 
tyrosine, F phenylalanine). This would mean that the 
first amino acid residue can be either aspartic acid (D) 
or asparagine (N) and the fourth residue can be either 
glutamic acid (E) or glutamine (Q), whereas in the 
calcium binding EGF-like domains, the first and fourth 
amino acids are always the negatively charged aspartic 
acid and glutamic acid. These residues are 100% 
conserved in all 44 calcium binding EGF domains of 
fibrillin 1. These negatively charged residues play an 
essential role in binding of the positively charged 
calcium ions, Ca2+, that are necessary for stabilization 
of the protein, as has been shown by NMR analysis and 
3d-imaging (figure 3)31,32. In Marfan patients the effect 
of mutations of the first aspartic acid of cbEGF 
domains has been shown by Hilhorst et al.33 The 
position and relative distance of the cysteine residues 
is also an essential feature of the EGF domains. The 
consensus amino acid sequence of the calcium binding 
EGF domains should be represented as: 
 
DX(D/N)ECXn(4-7)CXn(3-6)CXNXX(G/S)X(F/Y)XCXCXn(10-13)CX,  
 
where D is aspartic acid, N is asparagine, E is glutamic 
acid, C is cysteine, G is glycine, S is serine and X is 
any amino acid residue and n is a number in the 
indicated ranges. Any deviation from this consensus 
sequence should be considered pathogenic.  
 Another doubtful point in the publication of Loeys 
et al.8 is this: “Other missense mutations: segregation 
 
Figure 2. Example of evolutionary sequence conservation of the fibrillin 1 protein, using single letter amino 
acid code, showing cbEGF domains #36 and #37. Differences are marked with grey background. The proposed 
cbEGF consensus sequence is shown at the bottom. The essential amino acid residues in the consensus 
sequence are boxed. The numbers at the top refer to amino acid residues in the protein sequence. 
 
Figure 3. Three dimensional representation of cbEGF-
domains #36 and #37, created by iCn3D31,32. Disulfide 
bonds (yellow bars) and negatively charged amino 
acid residues are indicated. D = aspartic acid; E = 
glutamic acid. The N-terminal acidic residues of each 
domain are involved in calcium binding and are shown 
in red. Other negatively charged residues are shown in 
blue. These are pointed outward and are probably 
involved in interactions with other proteins.  
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in family if possible + absence in 400 ethnically 
matched control chromosomes, if no family history: 
absence in 400 ethnically matched control 
chromosomes.” The problem here is the threshold. For 
a dominantly inherited mutation it can be assumed that 
a carrier frequency in the population of >0.1% can be 
considered as evidence that the variant is not 
pathogenic. Probability calculation tells us that testing 
of 400 ethnically matched controls, a variant with a 
frequency of 0.1% can be found with a probability of 
1-0.999^400 = 0.33, or 33% chance of finding a variant 
with a population frequency of 0.1% in 400 control 
samples. Moreover, the presence of undiagnosed 
Marfan syndrome patients in the control population 
cannot be excluded, so even if a variant is found once 
in the control samples, it is still not clear weather that 
is evidence of a non-pathogenic variant.  
 Furthermore, the most common recurrent 
pathogenic mutation, deletion of the entire FBN1 
gene25, is not mentioned by Loeys et al.8 nor are multi-
exon deletions and duplications.  
 In the currently available exome databases, the 
population frequencies of variants can be easily 
checked in many populations. The frequencies in these 
databases are usually given as minor allele frequencies 
(MAF), which is not the carrier frequency of the 
variant, because every individual has two alleles, so the 
carrier frequency of rare variants is close to 2x the 
MAF. 
 In my experience, it is a very common error in the 
interpretation of mutations to think that it is necessary 
to look at the frequency in the same ethnic group as the 
patient, so it is assumed that the online databases 
cannot be used for patients from a population that is not 
represented. This is certainly not true for conclusions 
regarding the benign nature of variants that have a high 
frequency in ANY population. If, for example, a 
variant has a frequency of 5% in the Dutch population, 
this is sufficient evidence that the variant is NOT 
pathogenic, because we know that the frequency of 
Marfan syndrome in that population is nowhere near 
5%. If, on the other hand, a new variant in a patient is 
not found in any of the exome databases, it can still be 
a common neutral variant in the ethnic group to which 
the patient belongs, or it can be a rare benign variant. 
So, the reasoning presented by Dietz et al. when using 
400 control samples can only be used for a negative 
conclusion: if a variant is found in the control group 
with a frequency of >1% this is conclusive evidence of 
a benign variant. Without additional evidence of 
pathogenic nature of a variant, absence of the variant in 
the databases or in control samples cannot be used as 
conclusive evidence for pathogenic variants. On the 
other hand, presence of a variant at low frequency 
(<0.001) in the databases is not conclusive evidence of 
a benign variant.  
 
INDONESIAN MARFAN CASES 
 When discussing Marfan syndrome with MD’s in 
East Asian countries, I always hear that Marfan 
syndrome is extremely rare in East Asia. However, I 
am convinced that Marfan syndrome is very much 
underestimated in East Asia. As discussed before, in 
many Marfan families it is clear that within the 
families, not all carriers of the same pathogenic 
mutation have the clearly recognizable Marfan habitus 
with long limbs and long fingers2,3,4. However, they all 
have the high risk of aortic aneurysms and dissections, 
often leading to sudden death. The gnomAd (or ExAc) 
database33 contains exome sequences of some 9,000 
East Asian individuals without obvious disease. 
Checking this database for variants in FBN1, shows 
that the carrier frequency of known pathogenic 
mutations in the East Asian population is 0.000356, 
equaling 1 in 2800 individuals. This is a low estimate, 
because we only looked at variants that have been 
listed in CLINVAR as pathogenic, so pathogenic 
mutations that are specific for the East Asian 
population cannot be seen. The occurrence of 1 in 2800 
is very close to the known incidence in other 
populations and would mean a total of around 100,000 
patients in Indonesia. My point here is, that we don’t 
see the patients in East Asian countries such as 
Indonesia, because no one is looking. 
 In Semarang five families with clinical features of 
Marfan syndrome have been tested and 3 pathogenic 
variants were found, 2 of which were novel 
(publication in preparation). This shows that 1) Marfan 
syndrome is found in Indonesia and that 2) unique 
mutations are indeed present. This supports my thesis 
that 1 in 2800 is a low estimate.  
 
GENOTYPE PHENOTYPE CORRELATIONS 
 Despite the large phenotypic variation within 
families among carriers of the same mutation, some 
genotype – phenotype correlations have been found. 
Neonatal Marfan syndrome, a very severe form which 
is apparent at birth, is often caused by single exon 
deletions or exon skipping mutations, or missense 
mutations in the central part of the protein (encoded by 
Table 1. Frequencies of pathogenic (class 5) and likely pathogenic (class 4) variants in FBN1 in East Asian DNA 
samples, according to the Exome Aggregation database34. MAF is minor allele frequency. A MAF of 0.0178% 
means a carrier frequency of 1 in 2800. (cDNA numbers according to transcript NM_000138.4) 
Variant (DNA) Variant (protein) MAF East Asia % Pathogenicity class 
c.3128A>G p.(Lys1043Arg) 0.0120 5 
c.3172G>C p.(Gly1058Arg) 0.0058 4 
c.5546A>G p.(Asp1849Gly) 0.0058 5 
c.8123A>G p.(Asn2708Ser) 0.0640 4 
 Total 0.0876 Class 4+5 
 subtotal 0.0178 Class 5 
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exons 24-36)35,36. Nearly all exons of FBN1 consist of 
a multiple of 3 bases, so exon skipping or deletion do 
not lead to frameshift and nonsense mediated decay 
(NMD) of the mutant mRNA. This has probably played 
an important role during evolution, when the gene 
acquired a large number of almost identical functional 
domains, that necessitated a continuous reading frame. 
Truncating mutations and exon skipping or deletion 
outside exon 24-36 lead to a more severe phenotype 
than other mutations, probably because the short 
protein interferes with correct fibril formation37. 
Grouping patients based on effect of the FBN1 
mutations on the protein resulted in improved 
genotype-phenotype correlation38,39,40,41, with a 
striking effect on the response to medication42, as 
discussed below. One group was defined as 
”haploinsufficiency” (HN), with reduced production of 
normal fibrillin 1 due to deletion of the gene or null 
allele caused by nonsense mediated decay. The other 
group was defined as “dominant negative” (DN), 
which indicates that the production of mutant protein 
leads to a negative effect on the extracellular matrix.  
 
MEDICATION 
 The life-threatening symptoms of Marfan 
syndrome are the aortic root dilatation and thoracic 
aortic aneurysms and dissections, which may lead to 
sudden death. Therefore, prevention of aortic root 
dilatation and aneurysm growth is the target of 
developing drug therapy.  
 Habashi et al.43 have shown in a Marfan rat model, 
that the angiotensin 1 receptor antagonist losartan has 
a reducing effect on the growth of aortic diameter. This 
effect was stronger than blood pressure reduction by 
beta-blockers. It was concluded that losartan has a side-
effect on the TGF-β receptors. The involvement of 
TGF-β was based on the finding of increased nuclear 
phospho-smad2 in a (one!) patient with Marfan 
syndrome by Loeys et al.44, which led to the 
assumption that increased TGF-β activity is the cause 
of aortic aneurysms in Marfan syndrome and familial 
thoracic aortic aneurysms and dissections TAAD). 
This has led to the so-called TGF-β paradox in aortic 
aneurysms. However, in my opinion, the paradox is the 
result of an extremely simplified interpretation of the 
findings. Smad2 is a signal molecule that can be 
phosphorylated by at least 4 different receptors in 
response to different ligands, such as angiotensin II, 
myostatin, TGF-β1, -2 and -3 and activin-A45. So 
increased psmad2 is not evidence of increased TGF-β 
activity, as has been suggested46. A more logical 
candidate for the increased p-smad2 and for the effect 
of losartan is angiotensin II, through the effect of the 
drug on angiotensin II receptor type 142,47,48. The 
aggravating effect that has been found for 
inflammation in Marfan syndrome may be a result of 
local production of activin-A by mast cells and 
macrophages49.  
 Clinical trials with losartan have shown variable 
results. Studies in the Netherlands50 and the USA51 
showed a significant reduction in growth of aortic 
diameter in Marfan patients that used losartan, 
compared to patients that used beta blockers, whereas 
this was not confirmed by studies in France52 and 
Spain53. A meta analysis of clinical trials with losartan, 
comprising 1398 subjects, revealed no significant 
effect of losartan54. 
 We re-analyzed the data of the Netherlands study 
after grouping the patients based on effect of the FBN1 
mutations on the protein42. The groups were defined as 
described above The HN group comprised 35% of the 
patients and the DN group 65%. 
 Interestingly, a significant effect of losartan was 
found only in the HN group (p<0.001). This is in 
contrast with the idea that TGF-β is responsible for the 
growth of aortic diameter in Marfan patients. It has 
been assumed that TGF-β is easily released from 
mutant fibrillin 1, causing activation of the TGF-β 
receptors and smad2 phosphorylation, which 
supposedly could be inhibited by a side effect of 
losartan. If that were the case, losartan would be only 
effective in the DN group, whereas we demonstrated 
the opposite. Our study so far has not been confirmed 
by others, probably because in the other clinical trials 
no complete mutation analysis of all patients had been 
performed and no fibroblasts were available for RNA 
studies that are necessary to prove NMD. The 
discrepancy in the results of the clinical trials might be 
a result of distribution of DN and HN mutations. A 
relatively small number of HN mutations in the 
population would lead to a lack of statistical 
significance in the overall results. 
 We concluded from the finding that losartan is only 
effective in patients with HN mutations, that a more 
likely explanation for the effect of losartan is through 
angiotensin II42. HN mutations lead to a reduced 
production of fibrillin 1, which will cause a lower ratio 
of fibrillin to elastin and increased extensibility of the 
aorta. This will cause low blood pressure, which will 
induce activation of angiotensin II. This will cause 
phosphorylation of smad2 and-3 and changes in gene 
regulation, affecting the balance between proliferation 
and differentiation of smooth muscle cells, which is 
ultimately the cause of growth of the aortic diameter. 
Losartan, in this scenario, exerts an effect by inhibiting 
the angiotensin II receptor type 1, as it is supposed to 
do.  
 We have, as yet, no working hypothesis that 
explains the growth of aortic diameter in patients with 
a DN mutation.  
 
CONCLUSIONS 
 Marfan syndrome is an under-diagnosed condition 
in East Asia. The awareness of this condition is very 
low, even among health care professionals. Mutation 
testing of FBN1 is important for 1) Genetic counseling 
(recurrence risk; options for prevention). 2) Pre-
symptomatic diagnosis in families to assess individuals 
at risk. 3) Medication: the effect of losartan probably 
depends on the type of causative mutation in FBN1 
(HN or DN). Therefore, mutation testing may be 
important in choice of therapy. 
 Further studies are needed to elucidate the effect of 
losartan, especially in relation to the type of mutation. 
The interpretation of data from losartan research is 
obscured by the so-called TGF-β paradox in aortic 
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aneurysms. This paradox is the result of oversimplified 
interpretation of observations concerning smad2/3 
phosphorylation. There is no need for a paradox if the 
data are interpreted correctly.  
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